Ryan Conrad

Ryan Conrad is a Senior Economist at the U.S. Food and Drug Administration (FDA), where he specializes in health economics and empirical research aimed at informing policy development in healthcare. His work is focused on driving evidence-based decisions that impact drug evaluation and approval processes. Conrad has been involved in significant research related to the FDA's Breakthrough Therapy Designation, which aims to expedite the development of treatments for serious or life-threatening conditions that demonstrate substantial improvement over existing therapies.12

Conrad has a background that includes roles at various institutions, including a position as a Visiting Scholar at the Schaeffer Center for Health Policy and Economics. His academic contributions can be found in publications related to pharmaceutical policy and health economics, showcasing his expertise in these areas.45

On LinkedIn, he describes himself as an enthusiastic health economist dedicated to empirical research and policy development, indicating a strong commitment to enhancing healthcare outcomes through rigorous analysis.3